Abstract
In the first field trial with synthetic malaria vaccine SPf66 in a large population naturally exposed to malaria, 9957 persons greater than 1 year old and residing on the Colombian Pacific coast received three doses of the vaccine. To evaluate vaccine safety, clinical observations were made 30 min and 48 h after each immunization. There were no adverse reactions in 95.7% of cases. In the 4.3% of cases with adverse reactions, local induration and erythema were the most frequent. In a randomly selected group of vaccinees, anti-SPf66 antibody titers were measured after the third dose: 93% of the vaccinees raised antibodies to SPf66. Among these, 55% had titers greater than 1:1600. These results demonstrate the safety and immunogenicity of the SPf66 vaccine in a large field trial.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Amino Acid Sequence
-
Animals
-
Antibodies, Protozoan / biosynthesis*
-
Blood Pressure
-
Blotting, Western
-
Child
-
Child, Preschool
-
Enzyme-Linked Immunosorbent Assay
-
Female
-
Humans
-
Immunoglobulin G / biosynthesis
-
Infant
-
Malaria, Falciparum / prevention & control*
-
Male
-
Molecular Sequence Data
-
Plasmodium falciparum / immunology*
-
Protozoan Proteins / adverse effects
-
Protozoan Proteins / chemistry
-
Protozoan Proteins / immunology*
-
Protozoan Vaccines / adverse effects
-
Protozoan Vaccines / chemistry
-
Protozoan Vaccines / immunology*
-
Recombinant Proteins*
-
Vaccination / adverse effects
Substances
-
Antibodies, Protozoan
-
Immunoglobulin G
-
Protozoan Proteins
-
Protozoan Vaccines
-
Recombinant Proteins
-
SPf66 protein, Plasmodium